BOLD News and Press, Audentes Therapeutics Inc. From 12/02/19

Audentes Therapeutics (NASDAQ: BOLD ) agrees to be acquired by Astellas Pharma ( OTCPK:ALPMF ) for US$60/share in cash, representing a total equity value of ~US$3B; shares are halted. More news on: Audentes Therapeutics, Inc., Astellas Pharma Inc., Astellas Pharma Inc., Healthcare stocks...

- Complementary capabilities and resources of the two organizations create an industry-leading gene therapy company - Audentes to operate as an independent subsidiary, with access to the global scientific and development resources of Astellas to accelerate product development and manuf...

Agenus (NASDAQ: AGEN ) resumed with Buy rating and $6 (36% upside) price target at B. Riley FBR. Shares up  1%  premarket. More news on: Agenus Inc., Cabaletta Bio, Inc., Geron Corporation, Healthcare stocks news, Stocks on the move, , Read more ...

Image source: The Motley Fool. Audentes Therapeutics, Inc.   (NASDAQ: BOLD) Q3 2019 Earnings Call Nov 7, 2019 , 4:30 p.m. ET Operator Continue reading

Audentes Therapeutics, Inc. (BOLD) Q3 2019 Earnings Conference Call November 7, 2019 16:30 ET Company Participants Andrew Chang - Head, IR Matt Patterson - Chairman & CEO Natalie Holles - President & COO Conference Call Participants Dae Gon - SVB Leerink Chris Ray...

- BLA submission for AT132 for the treatment of XLMTM on-track for mid-2020; MAA on-track for second half of 2020 - Continued progress in Pompe Disease, DMD and DM1 pipeline programs: AT845 IND submitted and clinical start-up activities underway; AT702 IND on track for first quarter 2...

AAXN , AGO , AIRG , AL , ALTR , AMBC , AMH , AMPH , AQN , ARLO , ARNA , ATVI , AVID , BE , BEDU , BGNE , BKNG , BOLD , CABO , CDAY , CHUY , COLD , CORT , CTRE , CUTR , CWH , CYRX , DBX , DIS , EB , ENLC , ENV , FARM , FSLY , G , GDOT , GH , GPRO , GSBD...

Audentes Therapeutics, Inc. (Nasdaq: BOLD), a leading AAV-based genetic medicines company focused on developing and commercializing innovative products for serious rare neuromuscular diseases, will host a conference call and webcast to report its third quarter 2019 financial results and provi...

It can be hard for a non-scientist to judge the validity of a biotech's claims. Are this company's drugs going to be approved by the FDA? How valid is its research? These questions are almost impossible to answer. Even the scientists themselves can't be sure they're right until the clinical tria...

The following slide deck was published by Audentes Therapeutics, Inc. in conjunction with this Read more ...